• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

American College of Cardiology Conference (ACC)

Medtronic’s Resolute Integrity tops Abbott’s Xience | ACC 2016 roundup

April 5, 2016 By Brad Perriello

Medtronic’s Resolute Integrity stent tops Abbott’s Xience in Propel all-comers study Results from the Propel all-comers trial comparing Medtronic‘s (NYSE:MDT) Resolute Integrity drug-eluting stent showed it to be superior to the Xience stent made by rival Abbott (NYSE:ABT). The 1-year study followed 800 patients from the Propel trial who were treated with the Resolute Integrity device, […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5

Filed Under: Cardiovascular, Clinical Trials Tagged With: Abbott, American College of Cardiology Conference (ACC), Ethicon, Johnson and Johnson, Medtronic

Edwards Lifesciences hits all-time high on Sapien 3 study

April 5, 2016 By Brad Perriello

Shares in Edwards Lifesciences (NYSE:EW) hit an all-time high yesterday after the company reported strong 1-year data for its Sapien 3 replacement heart valve over the weekend. Results from the Partner II trial from 1,077 intermediate-risk patients showed that the Sapien 3 beat surgical valve replacement across a variety of safety endpoints, Irvine, Calif.-based Edwards said at […]

Filed Under: Cardiovascular, Clinical Trials, Replacement Heart Valves, Wall Street Beat Tagged With: American College of Cardiology Conference (ACC), Edwards Lifesciences

Boston Scientific halts EU sales of next-gen Watchman FLX anti-stroke device

April 5, 2016 By Brad Perriello

Boston Scientific (NYSE:BSX) reportedly halted European sales of its the next generation of its anti-stroke device, the Watchman FLX, after receiving reports of device embolization. Spokeswoman Trish Backes told TCTMD that there were 6 device embolizations in 207 (2.9%) European implantations of the Watchman FLX, an implant that designed to occlude the heart’s left atrial […]

Filed Under: Cardiac Implants, Cardiovascular Tagged With: American College of Cardiology Conference (ACC), Boston Scientific, Stroke

Boston Scientific’s Synergy stent at 2 years | ACC 2016 roundup

April 4, 2016 By Brad Perriello

Evolve II: 2-year data for Boston Scientific’s Synergy stent Boston Scientific‘s (NYSE:BSX) Synergy stent showed non-inferiority to its Promus Element Plus device after 12 months, according to data from the Evolve II trial presented yesterday at the annual conference of the American College of Cardiology. The Synergy stent’s bioresorbable polymer coating is designed to dissolve completely […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Filed Under: Cardiovascular, Clinical Trials Tagged With: Abbott, American College of Cardiology Conference (ACC), Boston Scientific, HeartFlow, Medtronic, stjudemedical

Fire & Ice: Medtronic’s Arctic Front ablation catheter as good as BioSense Webster’s ThermoCool | ACC 2016

April 4, 2016 By Brad Perriello

Results from a clinical trial presented today at the annual meeting of the American College of Cardiology showed that the Arctic Front ablation catheter made by Medtronic (NYSE:MDT) is noninferior to Johnson & Johnson (NYSE:JNJ) subsidiary BioSense Webster’s ThermoCool device in treating atrial fibrillation. The Fire & Ice study compared Arctic Front’s cryoballoon ablation technique with the […]

Filed Under: Cardiovascular, Catheters, Clinical Trials Tagged With: American College of Cardiology Conference (ACC), Biosense Webster, Johnson and Johnson, Medtronic

Medtronic touts more early data from drug-filled stent study | ACC 2016

April 4, 2016 By Brad Perriello

Medtronic (NYSE:MDT) yesterday touted early data from a clinical study of its drug-filled stent aimed at winning CE Mark approval in the European Union. The DFS is built using the Fridley, Minn.-based medical device giant’s Resolute Integrity and Resolute Onyx stents, using its “continuous sinusoid” and CoreWire technologies. It’s made with a “tri-layer” wire design in which the innermost […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Eluting Stents Tagged With: American College of Cardiology Conference (ACC), Medtronic

Edwards Lifesciences touts intermediate-risk data for Sapien devices | ACC 2016

April 4, 2016 By Brad Perriello

Data from a large trial of the Sapien line of replacement heart valves made by Edwards Lifesciences (NYSE:EW) are slated to be used to back bids for expanded indications in intermediate-risk patients. Presented over the weekend at the American College of Cardiology’s annual meeting in Chicago, results from the Partner II trial involving the Sapien XT and Sapien […]

Filed Under: Cardiovascular, Clinical Trials, Replacement Heart Valves Tagged With: American College of Cardiology Conference (ACC), Edwards Lifesciences

Boston Scientific’s Watchman misses 1 of 2 efficacy goals in PREVAIL trial

July 1, 2014 By Arezu Sarvestani Leave a Comment

Boston Scientific's Watchman misses 1 of 2 efficacy goals in PREVAIL trial

Boston Scientific (NYSE:BSX) this week unveiled full results from the PREVAIL clinical trial of the Watchman anti-stroke implant, largely agreeing with earlier reports that the device missed a co-primary endpoint for efficacy.

Filed Under: Cardiac Implants, News Well Tagged With: American College of Cardiology, American College of Cardiology Conference (ACC), Boston Scientific, Clinical Trials, Conference coverage

ACC14: The quickening pace of change

April 7, 2014 By MassDevice Contributors Network Leave a Comment

By Westby G. Fisher, MD, FACC

Westby Fisher

I just returned from the American College of Cardiology and wanted to write down a few of my 50,000-foot impressions from the meeting for, as the song goes, the times, they are a-changin’.

Filed Under: Blog, News Well Tagged With: American College of Cardiology, American College of Cardiology Conference (ACC), Conference coverage, Dr. Wes

ACC 2014: Conflicts in renal denervation, competition in valves

April 3, 2014 By Arezu Sarvestani Leave a Comment

fired/hired

The American College of Cardiology’s annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic’s (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.

Filed Under: News Well, Replacement Heart Valves Tagged With: ACC 2014, American College of Cardiology Conference (ACC), Boston Scientific, Clinical Trials, Conference coverage, Edwards Lifesciences, Hypertension, Renal

Looking back on a pretty sedate ACC

March 18, 2013 By MassDevice Contributors Network Leave a Comment

American College of Cardiology conference logo

By Stephen Simpson

Sometimes the major annual medical meetings are jam-packed with significant and market-moving data. And then sometimes they’re like this year’s American College of Cardiology conference, with relatively limited useful data from an investing perspective.

Filed Under: Blog, Cardiac Implants, News Well, Replacement Heart Valves Tagged With: Abbott, American College of Cardiology, American College of Cardiology Conference (ACC), Boston Scientific, Conference coverage, Contributed Blogs, Johnson and Johnson

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy